Shreyas Sen is the Elmore Associate Professor of Electrical and Computer Engineering at Purdue University, jointly affiliated with the School of Biomedical Engineering. He directs the Center for Internet of Bodies (C-IoB) and leads the SPARC Lab, focusing on circuits/systems for secure, energy-efficient body-centric communication and biomedical applications. Education: B.E. (Jadavpur University, 2006), M.S. & Ph.D. (Georgia Tech, 2009-2011). His research spans Human Body Communication (HBC), hardware security, IoT/IoB systems, and low-power sensing. Notable innovations include Electro-Quasistatic HBC (EQS-HBC) technology, which enables covert body-wire communication with 100x lower energy than conventional methods. Research Themes: Secure communication for medical wearables Physical layer security in IoT Ultra-low-power biosensors Side-channel attack mitigation in cryptographic ICs Publications: Over 200 papers in top venues (ISSCC, DAC, CICC, HOST) with focus on HBC systems, electromagnetic security, and biomedical circuits. Recent work explores EQS-HBC privacy properties (Nature Scientific Reports, 2019) and 350x current-domain signature attenuation for AES security (ISSCC 2020). Awards: NSF CAREER Award (2020) AFOSR Young Investigator (2016) MIT TR35 India (2018) 9 Best Paper Awards Intel Outstanding Researcher (2020) He advises over 20 students and leads industry collaborations through Ixana Inc. (founded 2020), commercializing EQS-HBC technology. Current efforts include EQS-based authentication systems and radiation dosimetry wearables.
Allison Ross Eckard, MD is Professor in the Departments of Pediatrics and Medicine at the Medical University of South Carolina (MUSC) College of Medicine, serving as Division Chief for Pediatric Infectious Diseases and Director of MUSC's Ryan White Pediatric HIV Clinic and HIV Transition Clinic. She maintains an adjunct faculty position at Emory University and holds board certification in Pediatrics and Pediatric Infectious Diseases. Her primary research focuses on metabolic, cardiovascular, and nutritional complications of chronic HIV and antiretroviral therapy across age groups, with emphasis on inflammation's role in comorbidities like cardiovascular disease and bone disorders. Current investigations include NIH R01-funded research on interventions for weight gain and abdominal fat in HIV, vitamin D supplementation, and statin therapy. She has published nearly 60 peer-reviewed papers on HIV pathogenesis and treatment optimization. Dr. Eckard co-chairs the DHHS panel for Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children and serves on the DHHS panel for Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV . Her clinical work specializes in comprehensive HIV care for children through young adults, with particular focus on adolescent/young adult transition issues and global health initiatives through Lespwa Timoun in Haiti. Recent efforts include developing COVID-19 treatment guidelines for children and school safety protocols. HIV Specialist certification (American Academy of HIV Medicine) Fellow, Infectious Diseases Society of America Fellow, Pediatric Infectious Diseases Society Fellow, HIV Medical Association Member, HIV Medical Association's 'Ending the HIV Epidemic' working group She leads MUSC's HIV education initiatives and serves as inpatient consultant for pediatric infectious diseases, with advanced training in tropical medicine. Her NIH-funded research examines targeted interventions to minimize comorbidity development in HIV, while her clinical leadership spans the Ryan White HIV program, transition clinics, and global health partnerships.
Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.
Bradley D. Olsen is a full professor in the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT), where he leads research at the intersection of polymer science, soft matter physics, and bioengineering. His work focuses on designing materials for critical applications in biotechnology, hemostasis, and sustainable polymer development while advancing fundamental understanding of polymer network mechanics and self-assembly. Education: Ph.D. in Chemical Engineering, University of California Berkeley (2007) S.B. in Chemical Engineering, Massachusetts Institute of Technology (2003) Olsen's research spans protein-based materials, block copolymer phase behavior, and mechanochemical hydrogels. He has pioneered methods for quantifying polymer network topology, developing hemostatic nanoparticles, and creating bio-inspired materials for selective biomolecular transport and medical applications. His recent publications emphasize data-driven approaches to polymer characterization and educational outreach in materials science. Scientific Awards: American Physical Society (APS) Fellow (2023) Fulbright Amazonia Scholar (2023) Alexander and I. Michael Kasser Chair in Chemical Engineering (2021) ACS Macro Letters Young Investigator Award (2021) MIT Committed to Caring Honor (2019) AIChE Owens Corning Early Career Award (2019) APS Dillon Medal (2018) Kavli Emerging Leader in Chemistry (2017) ACS Polymer Division Fellow (2016) Camille Dreyfus-Teacher Scholar (2015) Alfred P. Sloan Research Fellow (2014) NSF Career Grant (2013) NIH Postdoctoral Fellowship (2008-2009) Hertz Fellow (2003-2007) Barry M. Goldwater Scholarship (2002) Olsen has received significant grant support including NSF Career (2013) and AFOSR (2012) awards. His teaching activities include innovative international outreach like the 2025 soccer-themed science camp in Brazil. The Olsen Group at MIT explores advanced materials with applications ranging from trauma care to sustainable polymers.
Manoj Sachdev is a Professor in the Department of Electrical and Computer Engineering at the University of Waterloo, Faculty of Engineering. His research focuses on semiconductor devices, low-power electronics, and secure hardware systems. He leads projects in flexible electronics, nanotechnology, and radiation-hardened circuits, with applications in displays, memory technologies, and biomedical sensors. His work integrates advanced materials science with circuit design to address challenges in energy efficiency and security. Education: Not explicitly stated in provided text. Research interests span thin-film transistors (TFTs), resistive switching memories, neuromorphic computing, and physically unclonable functions (PUFs). Recent efforts include developing low-power circuits for flexible substrates and secure microprocessors. His contributions to semiconductor device physics and integration techniques have advanced applications in wearable electronics and medical diagnostics. Publications highlight innovations in low-power flip-flops, energy-efficient display drivers, and memristor-based systems. He collaborates on interdisciplinary projects combining photonics, nanoelectronics, and biomedical engineering. Awards: None explicitly listed in provided text. Grants and advising: Advises on semiconductor fabrication, secure hardware design, and radiation effects in electronics. Leads research groups focused on next-generation memory technologies and flexible integrated systems. Labs/Teams: Active in the University of Waterloo's semiconductor and flexible electronics research clusters, contributing to both academic and industry partnerships.
Professor Victor Fung is a leading academic in neurology and motor control at the Sydney Medical School , University of Sydney. He serves as Director of the Movement Disorders Unit at Westmead Hospital and holds prominent roles in the International Parkinson and Movement Disorder Society (President) and the Asia Pacific Affairs Committee of the Australian and New Zealand Association of Neurologists. His research focuses on Parkinson's disease , dystonia , tremor , and movement disorder genetics , with over 250 peer-reviewed publications and an h-index of 61. His work spans Clinical trials for Parkinson's treatments (e.g., foslevodopa/foscarbidopa infusion, incobotulinumtoxinA) Genetic studies on dystonia and Parkinsonism Neurophysiological assessments of tremor and balance Development of screening tools for dystonia and Parkinson's complications Key article trends highlight genetic diversity in dystonia, neuroinflammatory mechanisms in tremor, and behavioral neurology in Parkinson's disease. He contributes to editorial boards of npj Parkinson's Disease , Journal of Clinical Movement Disorders , and Faculty Opinions . While no explicit student lists are provided, his collaborations span global institutions. His clinical work at Westmead Hospital addresses device-assisted therapies and complex movement disorders.
Pan Xu is a tenure-track assistant professor with joint appointments in the Department of Biostatistics & Bioinformatics, Department of Computer Science, and Department of Electrical & Computer Engineering at Duke University. Previously, Xu was a Postdoctoral Scholar Research Associate at Caltech's Department of Computing and Mathematical Science and earned a Ph.D. in Computer Science from UCLA. Xu's research focuses on developing computationally- and data-efficient machine learning algorithms with strong empirical performance and theoretical guarantees. Xu's research interests center around Machine Learning with broad applications in Artificial Intelligence, Data Science, Optimization, Reinforcement Learning, and High Dimensional Statistics. The research specifically targets real-world problems in Bioinformatics and Healthcare, with recent work emphasizing distributionally robust decision making, efficient exploration strategies, and multi-agent systems. Xu has developed novel algorithms that address the challenges of exploration in sequential decision making and robustness to distributional shifts between training and deployment environments. Xu's recent publications demonstrate a strong trend toward developing theoretically grounded yet practical algorithms for reinforcement learning and bandit problems, with particular emphasis on distributionally robust methods, efficient exploration techniques, and applications to healthcare. The work spans both theoretical analysis (providing minimax optimal regret bounds) and practical implementations (validated on benchmarks like Atari games and real healthcare datasets). Whitehead Scholar award from Duke University School of Medicine (2023) Best Paper Award at ACM FAccT 2023 for Queer In AI paper PIMCO Postdoctoral Fellowship in Data Science (2022) TMLR Featured Certification (2023) NSF award on approximate sampling based exploration (2023) Xu actively mentors multiple Ph.D. students across Duke's Biostatistics & Bioinformatics, Computer Science, and Electrical & Computer Engineering programs, with several alumni now pursuing doctoral studies at top institutions. The research group has secured competitive funding including an NSF award for approximate sampling based exploration for sequential decision making. Xu serves as an action editor for TMLR and as an area chair for major conferences including ICML, NeurIPS, AAAI, ICLR, and AISTATS. Xu leads a dynamic research group focused on sequential decision making, with projects spanning theoretical algorithm development, implementation of practical systems, and applications to healthcare and bioinformatics. The group maintains active collaborations across Duke's medical and engineering schools, with recent work applying machine learning to epidemic forecasting during the pandemic.
Marc Erich Latoschik is a Professor in the Department of Human-Computer Interaction at the University of Würzburg, Germany. He previously held roles at Bayreuth University, Bielefeld University, and FHTW Berlin. His research focuses on virtual and augmented reality, embodiment, human-computer interaction, and applications in health, education, and social systems. Education: Completed his PhD in 2001 at Bielefeld University with a thesis on multimodal interaction in virtual reality. Research Interests: Embodied interaction, virtual embodiment, presence and plausibility in VR/AR, avatar design, social virtual reality, health applications (e.g., VR therapy for body image issues), and XR security/privacy. Active in developing frameworks like Reality Stack I/O and MAIL for VR/AR research. Key Projects: ViTraS study on body image exercises in VR, avatars for mass use via smartphone reconstruction, and motion-based biometrics in XR. Collaborates with medical teams on cybersickness detection and emergency training simulations. Labs/Teams: Leads research groups on immersive technologies and social VR applications. Involved in interdisciplinary projects combining HCI, AI, and healthcare.
Dr. Hongtu Zhu is the Kenan Distinguished Professor of Biostatistics, Statistics, Radiology, Computer Science, and Genetics at the University of North Carolina at Chapel Hill (UNC). He holds affiliations with the Gillings School of Global Public Health and leads the Biostatistics and Imaging Genomics Analysis Lab. His expertise spans statistical learning, medical imaging, AI, and big data integration, with a focus on precision medicine and biomedicine. Dr. Zhu earned his PhD in Statistics from The Chinese University of Hong Kong (2000) and has held prior roles including DiDi Fellow/Chief Scientist (2018-2020) and Bao-Shan Jing Endowed Professor at MD Anderson Cancer Center (2016-2018). He has published over 345 peer-reviewed articles in top-tier journals like Nature, Science, and JASA, and actively contributes to editorial roles including Coordinating Editor of JASA. His research interests include neuroimaging analysis, knowledge graphs, and AI applications in healthcare. Notable awards include the COPSS Snedecor Award (2025), IEEE Fellowship (2025), and IMS Medallion (2027). He has mentored over 80 PhD students/postdoctoral fellows and serves on NIH grant review panels and professional organizations like the ASA's Section on Statistics in Imaging. Key Contributions: Imaging genomics, brain connectivity studies, ridesharing market optimization, medical AI frameworks Lab Innovations: Brain Imaging Genetics Knowledge Portal, Biomedical Knowledge Graph Interface Teaching: Advanced biostatistics courses (Generalized Linear Models, Deep Learning in Biomedicine) Recent work explores causal inference in healthcare, X chromosome's role in neurobiology, and AI ethics in medical vision-language models. His interdisciplinary projects bridge statistics, computer science, and clinical practice to address complex biomedical challenges.
Nancy J. Brown, M.D., is the Jean and David W. Wallace Dean of the Yale School of Medicine and holds the C.N.H. Long Professorship in Internal Medicine. Previously, she served as Chair of Vanderbilt Department of Medicine and Physician-in-Chief of Vanderbilt University Medical Center (2010–2020). Her academic career spans over three decades, with leadership roles in clinical care, research, and medical education. Education: MD, Harvard University (1986) AB in Molecular Biophysics and Biochemistry, Yale College (1981) Internship and Residency in Medicine, Vanderbilt University (1989) Fellowship in Clinical Pharmacology, Vanderbilt University (1991) Chief Resident, Vanderbilt University (1992) Research Interests: Dr. Brown’s work focuses on the renin-angiotensin-aldosterone system’s role in cardiovascular disease, hypertension, and thrombosis. Her lab has elucidated mechanisms linking aldosterone, bradykinin, and ACE inhibitors to inflammation, fibrosis, and cardiovascular risk. Current studies explore neprilysin inhibitors in heart failure and incretin-based therapies’ cardiovascular effects. Key Contributions: Identified genetic variants and African ancestry as risk factors for ACE inhibitor-associated angioedema Developed Vanderbilt’s Master of Science in Clinical Investigation program (2000) Advocated for physician-scientist development through leadership roles in NIH councils and professional organizations Recognition: Recipient of the Harriet Dustan Award, August M. Watanabe Prize, and Robert H. Williams Distinguished Chair of Medicine. Elected to the National Academy of Medicine and American Academy of Arts & Sciences. Labs/Teams: Leads the Yale School of Medicine’s cardiovascular research initiatives, focusing on translational studies of RAAS pathways and drug mechanisms.
Zion Zibly, MD, MBA is an Associate Professor in the Department of Neurosurgery at Yale School of Medicine . He holds multiple leadership roles including Director of the Center of Neuromodulation , Director of the Center of Neurosurgical Cancer Pain , and Head of Stereotactic & Functional Neurosurgery and the Focused Ultrasound Institute . Previously served as Chair of Neurosurgery at Sheba Medical Center after graduating from Technion’s Faculty of Medicine (MD) and Coller School of Management (MBA). Research Interests: Specializes in Neuromodulation for movement disorders (Parkinson’s, tremors, dystonia), Deep Brain Stimulation , Gene Therapy for pediatric neurodegenerative conditions, Oncological Neurosurgery , and Neurological Pain Management . Combines Functional Neurosurgery with Focused Ultrasound technology. Scientific Contributions: Participated in pioneering Alzheimer’s brain stimulator procedures and Gene Therapy applications. Active member of the North American Association of Functional Neurosurgery and Israeli Neurosurgical Society . Clinical Expertise: Implantation of electrostimulators for Parkinson’s and essential tremor, treatment of Benign/Malignant CNS Tumors , and management of Neurological Pain Conditions . Affiliated with Yale Cancer Center and Center for Brain & Mind Health .
Jennica Zaro, PhD, serves as Associate Professor of Pharmacology and Pharmaceutical Sciences at the University of Southern California (USC) School of Pharmacy and Assistant Dean for Assessment in the Office of Graduate Education and Postdoctoral Studies. Previously, she held academic leadership roles at West Coast University School of Pharmacy and directed the Translational Research and Histology laboratories at USC Mann. Education: PhD in Pharmaceutical Sciences, University of Southern California BS, Stockton University Her pioneering research focuses on engineering recombinant fusion proteins for targeted drug delivery, particularly developing liver-specific insulin therapies for diabetes and pH-sensitive nanoconstructs for tumor targeting. This interdisciplinary work bridges protein engineering, nanomedicine, and translational pharmacology to create site-specific therapeutic systems with enhanced efficacy and reduced side effects. Analysis of her recent publications reveals a cohesive research trajectory centered on protein-drug conjugates, with significant contributions in pH-responsive delivery systems (2017-2018) and liver-targeted insulin analogs (2016-2018). Her work consistently appears in high-impact journals like Journal of Controlled Release and Biomaterials , demonstrating expertise in translating molecular designs into therapeutic applications. Scientific Awards: Most Innovative Award (2017, West Coast University) Advisor of the Year Award (2017, West Coast University, School of Pharmacy) Dr. Zaro has secured substantial research funding as Principal Investigator for NIH National Cancer Institute projects (2013-2016) and USC Ming Hsieh Institute grants (2014-2015), plus consultancy roles with Juvenile Diabetes Research Foundation (2016-2018). She actively shapes national research policy through service on NIH and UK Medical Research Council review panels and the American Foundation for Pharmaceutical Education Board of Grants. Her laboratory expertise includes the Translational Research and Histology core facilities at USC Mann, and she maintains active roles in professional organizations including the Controlled Release Society, American Association of Pharmaceutical Scientists, and American Association of Colleges of Pharmacy.
Bruce H. Alexander, PhD, serves as Professor and Division Head of Environmental Health Sciences at the University of Minnesota's School of Public Health. His educational background includes a PhD in Epidemiology from the University of Washington (1994), an MS in Environmental Health from Colorado State University (1987), and a BS in the same field from Colorado State University (1984). Dr. Alexander is an occupational and environmental epidemiologist whose research spans environmental determinants of cancer and respiratory disease, injury prevention and control, One Health approaches, agricultural population health, and global health initiatives. His work emphasizes multidisciplinary approaches to address complex public health problems and building public health research and practice capacity. His expertise encompasses occupational and environmental epidemiology, environmental exposures, infectious disease, injuries, occupational health, One Health frameworks, global health, and agricultural health. Analysis of his recent publications (2019-2024) reveals a continued focus on occupational exposures, environmental health risks, and injury epidemiology across diverse populations and settings. His research demonstrates methodological diversity including cohort studies, systematic reviews, and meta-analyses addressing chemical exposures, UV radiation risks, temperature-related injuries, and mineral particle exposures in mining contexts. Scientific Recognition Member, Delta Omega Honorary Society in Public Health Mayo Professor of Public Health, School of Public Health, University of Minnesota (2016) Faculty Excellence Award, Division of Environmental and Occupational Health, University of Minnesota (2002) Dr. Alexander maintains active professional affiliations with major epidemiological organizations including the Society for Epidemiologic Research, International Society for Environmental Epidemiology, American College of Epidemiology, International Commission on Occupational Health, and Delta Omega. His work through the Upper Midwest Agricultural Safety and Health Center (UMASH) and Midwest Center for Occupational Health and Safety demonstrates commitment to translating research into practice for worker safety and health.
Juliane Nguyen, PhD, is a Professor in the Department of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. She serves as Vice Chair and Director of Graduate Admissions in her department and holds an adjunct appointment as Professor of Biomedical Engineering. Dr. Nguyen is also a member of the UNC Lineberger Comprehensive Cancer Center, where she applies molecular engineering approaches to develop innovative therapeutic solutions. Dr. Nguyen's research focuses on molecular engineering to advance protein-based therapeutics, live biotherapeutics (including engineered probiotic yeast), and extracellular vesicles. Her lab develops cutting-edge technologies to treat diverse conditions including cancer, myocardial infarction, chemotherapy-induced cardiotoxicity, and inflammatory bowel diseases. Her interdisciplinary approach integrates molecular engineering, pharmaceutical sciences, and bioinformatics to create complex biologics with exceptional safety and efficacy profiles. Key research areas include developing therapeutics for cardiac repair, genetically encoded materials targeting tumor-associated macrophages, live biotherapeutics for inflammatory bowel diseases using engineered probiotic yeast, and auxetic patches for dynamic organ repair. Analysis of Dr. Nguyen's recent publications reveals a strong focus on translational research with significant contributions to cardiac repair technologies, cancer immunotherapy, inflammatory bowel disease treatments, and advanced biomaterials. Her work consistently bridges fundamental molecular engineering with clinical applications, particularly in the areas of targeted drug delivery, extracellular vesicle therapeutics, and engineered live biotherapeutics. The research demonstrates a clear trajectory toward developing clinically viable solutions for previously challenging medical conditions. Dr. Nguyen has received numerous prestigious awards and honors including the NSF CAREER Award (2018), Eshelman Innovation Award (2020), and recognition as a Fellow of the Controlled Release Society (2023). She was appointed as a Standing Member of the NIH Drug and Biologic Therapeutic Delivery Study Section (2023-2025) and serves as Executive Editor of Advanced Drug Delivery Reviews since 2021. Her Galenus Guest Professorship at ETH Zuerich (2024) and keynotes at major conferences highlight her international recognition in the field. As Director of Graduate Admissions and an active mentor, Dr. Nguyen has advised numerous PhD and Master's students who have co-authored significant publications with her. Her research is supported by competitive grants including the NSF CAREER Award and other NIH-funded projects. The Nguyen Lab maintains strong collaborations across disciplines, particularly with cardiology, oncology, and biomedical engineering researchers. She leads an interdisciplinary team focused on translating molecular engineering breakthroughs into clinically impactful therapies. The Nguyen Lab operates as a dynamic, interdisciplinary research environment combining expertise in molecular engineering, pharmaceutical sciences, and bioinformatics. The lab's mission is to revolutionize medicine by developing next-generation therapeutics that target diseases at the molecular level. Current projects focus on translating cutting-edge research into life-changing therapies for patients suffering from cancer, myocardial infarction, colitis, and other challenging conditions. The lab's innovative approach to biomolecular engineering positions it at the forefront of developing safe, effective, and personalized therapeutic solutions.
Jeffrey T. Jensen, M.D., M.P.H., is the Leon Speroff Professor and Vice Chair for Research in the Department of Obstetrics and Gynecology at Oregon Health & Science University (OHSU). He holds joint appointments as Professor of Public Health and Preventive Medicine and serves as a Core Scientist at the Oregon National Primate Research Center (ONPRC). Dr. Jensen completed his medical degree at Emory University, a Master of Public Health at the University of Washington, and residency training at OHSU. Research Focus: Dr. Jensen leads translational and clinical research programs focused on contraceptive innovation. His work emphasizes nonhuman primate models to develop: Novel contraceptive agents targeting oocyte-specific pathways Non-surgical permanent contraception methods Optimized emergency contraception for diverse populations He directs OHSU's Women’s Health Research Unit and the Gates Foundation-funded Oregon Permanent Contraception Research Center (OPERM). Recent Publications: His 15 most recent articles (2023-2025) demonstrate concentrated expertise in: Advanced hormonal contraceptive formulations (IUDs, vaginal rings, oral agents) Weight-adjusted dosing strategies for emergency contraception Biomarker validation for contraceptive efficacy monitoring Real-world assessment of bleeding pattern management Leadership & Collaboration: Dr. Jensen is Principal Investigator of the NICHD Contraception Clinical Trials Network and collaborates with global health organizations (CONRAD, FHI360, Population Council). He serves as Deputy Editor for the journal Contraception and consults for multiple pharmaceutical companies on product development.
